Krazati (adagrasib) — United Healthcare

Initial criteria

• Diagnosis of pancreatic adenocarcinoma
• Presence of KRAS G12C mutation
• Disease is recurrent OR advanced OR metastatic
• Patient has received at least one prior systemic therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Krazati therapy

Approval duration

12 months